Abstract
Ischemic colitis (CI) is a common form of ischemic injury, which evolves as a consequence of decreased arterial blood flow to the colon. In general, CI is attributed to an elderly with multiple comorbidities; however, it may also occur in young or middle-aged individuals. The etiology of CI is multifactorial and the clinical presentation varies upon the severity of deprivation of the intestinal blood flow, and the development of the microvasculature plexus. Multiple case reports have associations with medications, vascular disorders, pathogens and hematologic diseases. Occlusive and nonocclusive diseases are the major mechanisms, which are simultaneously the causative factor of intestinal ischemia. In this review, we discuss major factors predisposing to occurrence of CI and analyze the mechanisms of action of several classes of medications currently used. We also suggest possible therapies and discuss the latest reports, which may lead to the discovery of novel pharmacological targets for future anti-CI drugs to be used in the clinical treatment.
Keywords: Intestinal ischemia, ischemic colitis, management, risk factors.
Current Drug Targets
Title:Ischemic Colitis: Current Diagnosis and Treatment
Volume: 16 Issue: 3
Author(s): Paula Mosinska and Jakub Fichna
Affiliation:
Keywords: Intestinal ischemia, ischemic colitis, management, risk factors.
Abstract: Ischemic colitis (CI) is a common form of ischemic injury, which evolves as a consequence of decreased arterial blood flow to the colon. In general, CI is attributed to an elderly with multiple comorbidities; however, it may also occur in young or middle-aged individuals. The etiology of CI is multifactorial and the clinical presentation varies upon the severity of deprivation of the intestinal blood flow, and the development of the microvasculature plexus. Multiple case reports have associations with medications, vascular disorders, pathogens and hematologic diseases. Occlusive and nonocclusive diseases are the major mechanisms, which are simultaneously the causative factor of intestinal ischemia. In this review, we discuss major factors predisposing to occurrence of CI and analyze the mechanisms of action of several classes of medications currently used. We also suggest possible therapies and discuss the latest reports, which may lead to the discovery of novel pharmacological targets for future anti-CI drugs to be used in the clinical treatment.
Export Options
About this article
Cite this article as:
Mosinska Paula and Fichna Jakub, Ischemic Colitis: Current Diagnosis and Treatment, Current Drug Targets 2015; 16 (3) . https://dx.doi.org/10.2174/1389450116666150113120549
DOI https://dx.doi.org/10.2174/1389450116666150113120549 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Citicoline and Retinal Ganglion Cells: Effects on Morphology and Function
Current Neuropharmacology Opportunities and Challenges for Host-Directed Therapies in Tuberculosis
Current Pharmaceutical Design Pharmacological Therapy of Cushings Syndrome: Drugs and Indications
Mini-Reviews in Medicinal Chemistry Pharmacological Countermeasures for the Acute Radiation Syndrome
Current Molecular Pharmacology Calcitonin Gene-Related Family Peptides in Vascular Adaptations, Uteroplacental Circulation, and Fetal Growth
Current Vascular Pharmacology Micropropagation: A Tool for the Production of High Quality Plant-based Medicines
Current Pharmaceutical Biotechnology Hypertension in Diabetes: Optimal Pharmacotherapy
Cardiovascular & Hematological Agents in Medicinal Chemistry 6-Oxo-Morphinane Oximes: Pharmacology, Chemistry and Analytical Application
Current Medicinal Chemistry The Impact of Various Blood Pressure Measurements on Cardiovascular Outcomes
Current Vascular Pharmacology Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry The Role of Pro-Inflammatory Molecules and Pharmacological Agents in Acute Pancreatitis and Sepsis
Inflammation & Allergy - Drug Targets (Discontinued) Bcl-2 Proteins: Targets and Tools for Chemosensitisation of Tumor Cells
Current Medicinal Chemistry - Anti-Cancer Agents Cardiovascular Effects Mediated by Imidazoline Drugs: An Update
Cardiovascular & Hematological Disorders-Drug Targets Recent Insights into COVID-19 in Children and Clinical Recommendations
Current Pediatric Reviews Pathophysiological Roles of Renin-Angiotensin System on Erythropoietic Action
Current Hypertension Reviews Nocturia in Obstructive Sleep Apnea-Hypopnea Syndrome: An Underappreciated Symptom
Current Respiratory Medicine Reviews Does the Association Between Anxiety and Parkinsons Disease Really Exist? A Literature Review
Current Psychiatry Reviews The Role of Procalcitonin in Sepsis and Septic Shock
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents COVID-19 Invades Several Important Organs other than the Lungs: Organs Crosstalk
Coronaviruses Multicenter Randomized Controlled Trial for the Treatment of Ulcerative Colitis with a Leukocytapheresis Column
Current Pharmaceutical Design